Adjuvant therapy for breast cancer — treatment after surgicalremoval of the tumor — is a major therapeutic advancethat has had a considerable effect on prolonging disease-freeand overall survival. Not all patients benefit from adjuvanttherapy, however, and certain types of adjuvant therapy arenot appropriate for some patients. For example, adjuvant treatmentwith tamoxifen, a selective estrogen-receptor modulator, hasimproved the 15-year survival rate among women with estrogen-receptor–positivebreast cancer by 31%, but it does not benefit women with estrogen-receptor–negativedisease.1 Trastuzumab, a monoclonal antibody against the humanepidermal growth factor receptor type 2 (HER2), is associated. . . [Full Text of this Article]
Source Information
From the Division of Hematology–Oncology, Weill Cornell Medical College, Cornell University Medical Center, New York.
Hudis, C., Dang, C.
(2008). The Taxane Limbo: How Low Can We Go?. JNCI J Natl Cancer Inst
100: 761-763
[Full Text]
Roukos, D. H., Ferretti, G., Felici, A., Cognetti, F., Mehta, R., Nash, I., Hayes, D. F., Berry, D., Moore, A.
(2008). HER2 and Response to Paclitaxel in Node-Positive Breast Cancer. NEJM
358: 197-199
[Full Text]
(2007). Who Needs a Taxane? Tailoring Breast Cancer Therapy. JWatch Oncology and Hematology
2007: 1-1
[Full Text]
Previous
